| 24/12/2021 |
Second Supply Agreement for Anagenics’ FGF5 Inhibitors |
| 15/12/2021 |
Change of Company Name |
| 09/12/2021 |
Annual General Meeting – CEO Presentation |
| 09/12/2021 |
Release of Shares from Voluntary Escrow |
| 09/12/2021 |
Results of Annual General Meeting |
| 10/11/2021 |
Cellmid receives R&D tax credit |
| 09/11/2021 |
Letter to Shareholders – Notice of Annual General Meeting |
| 09/11/2021 |
Notice of Annual General Meeting – Proxy Form |
| 09/11/2021 |
Proposed issue of securities – CDY |
| 08/11/2021 |
Final Director’s Interest Notice – Eck-Thompson |
| 08/11/2021 |
Initial Director’s Interest Notice – Christopher |
| 08/11/2021 |
Jobkeeper Payments Notification |
| 05/11/2021 |
Becoming a substantial holder from HNG |
| 02/11/2021 |
Application for quotation of securities – CDY |
| 02/11/2021 |
Appointment of Non-Executive Director |
| 02/11/2021 |
BLC Cosmetics Acquisition Completed |
| 02/11/2021 |
Cleansing Notice |
| 22/10/2021 |
General Meeting Presentation |
| 19/10/2021 |
Appendix 4C and Quarterly Activity Report |
| 13/10/2021 |
Notification of cessation of securities – CDY |
| 26/09/2021 |
Investor Webinar |
| 24/09/2021 |
Change of Director’s Interest Notice – Halasz |
| 22/09/2021 |
Letter to Shareholders – Notice of General Meeting |
| 22/09/2021 |
Notice of General Meeting/Proxy Form |
| 20/09/2021 |
Annual Report to shareholders |
| 20/09/2021 |
Appendix 4G and Corporate Governance Statement |
| 16/09/2021 |
BLC Cosmetics to merge with Cellmid |
| 16/09/2021 |
Cellmid to Acquire BLC Cosmetics Pty Ltd |
| 16/09/2021 |
Proposed issue of securities – CDY |
| 19/08/2021 |
Appendix 4E and FY21 Financial Report |
| 20/07/2021 |
Appendix 4C and Quarterly Activity Report |
| 09/07/2021 |
Notification of cessation of securities – CDY |
| 02/07/2021 |
MarketLit Investor Conference Presentation |
| 17/06/2021 |
Cellmid Reports Record QVC Sales |
| 10/06/2021 |
FGF5 Inhibitors Supply Agreement – Additional Information |
| 10/06/2021 |
Release of Shares from Voluntary Escrow |
| 08/06/2021 |
Supply Agreement for Cellmid’s FGF5 Inhibitors |
| 02/05/2021 |
Investor Briefing and Presentation |
| 30/04/2021 |
Chinese Import Permits Received |
| 29/04/2021 |
Agreement Signed for Sale of Lyramid Limited |
| 29/04/2021 |
Investor Briefing |
| 23/04/2021 |
Appendix 4C and Quarterly Activity Report |
| 01/04/2021 |
Appendix 2A |
| 01/04/2021 |
CDYOA Top20 and Distribution List |
| 01/04/2021 |
Change of Director’s Interest Notice – Cross |
| 01/04/2021 |
Change of Director’s Interest Notice – Eck |
| 01/04/2021 |
Change of Director’s Interest Notice – Gordon |
| 01/04/2021 |
Change of Director’s Interest Notice – Halasz |
| 31/03/2021 |
Proposed issue of Securities – CDY |
| 31/03/2021 |
Rights Issue Closed with Strong Demand |
| 31/03/2021 |
Supplementary Prospectus |
| 25/03/2021 |
Cellmid receives R&D tax credit |
| 12/03/2021 |
Dispatch of Rights Issue Documentation Completed |
| 10/03/2021 |
Investor Presentation |
| 09/03/2021 |
Commencement of the Trading of Rights on the ASX |
| 08/03/2021 |
Appendix 3B |
| 08/03/2021 |
Pause in Trading |
| 08/03/2021 |
Rights Issue |
| 08/03/2021 |
Rights Issue Prospectus |
| 25/01/2021 |
Appendix 4C and Quarterly Activity Report |
| 24/01/2021 |
Cellmid Receives First Order From Chinese Distributor |
| 15/01/2021 |
Appendix 2A |
| 04/01/2021 |
Final Director’s Interest Notice – King |
